DOI:

Percutaneous transfemoral transcatheter aortic valve implantation (pTAVI): a single-centre experience comparing general with local anaesthesia

Venugopal V., Drury-Smith M., Lakshmanan S., Fayaz M., Cotton J., Bhabra M., Khogali S.

Single and multicentre TAVI registries

Percutaneous transfemoral transcatheter aortic valve implantation (pTAVI): a single-centre experience comparing general with local anaesthesia

Aims: Transcatheter aortic valve implantation (TAVI) is the treatment of choice for high-risk patients with aortic stenosis. Percutaneous transfemoral vascular access is the preferred and least invasive approach (pTAVI) and may be performed under local anaesthetic (LA) in suitable patients. Other vascular approaches are surgical (sTAVI) and require general anaesthesia (GA). We aim to describe the vascular approaches and modes of anaesthesia used in our CoreValve TAVI programme and evaluate, as well, the vascular outcomes of pTAVI using the Prostar pre-closure device.

Methods and results: Consecutive TAVI procedures (n=106) between October 2008 and April 2012 were analysed and data pertaining to baseline characteristics, delivery approaches, anaesthesia and hospital stay were examined. All patients who had TAVI via the percutaneous femoral approach were specifically asked about new claudication symptoms on follow-up and those who had successful device (Prostar) closure of femoral arteriotomy had quantitative assessment of femoral angiographic stenosis (QFA). Vascular access was assessed routinely by aorto-ilio-femoral angiography; vessel diameter (minimum 6 mm), tortuosity and calcification were the key determinants of suitability. Each case was reviewed by a multidisciplinary team (MDT) involving cardiologists, surgeons and anaesthetists. The transfemoral approach was preferred wherever appropriate. LA was considered for all transfemoral cases taking into account the body habitus and patient psychology. The delivery approach was transfemoral in 84 (79%), subclavian in 17 (16%) and direct aortic in five (5%) cases. Of the 84 transfemoral cases 47 (56%) were performed with GA and the remaining 37 (44%) under LA. The mean logistic EuroSCORE in the GA group (22%) was significantly higher than in the LA group (16%) (p=0.019). Other variables like age, gender and body mass index (BMI) were comparable as was the duration of hospital stay (11.3 [GA] vs. 9.8 [LA]). Closure of the femoral arteriotomy using the Prostar device was successful in all but five cases (79/84, 94%). In one case, emergency bypass grafting was necessitated by avulsion of the iliac artery during removal of the sheath. QFA was performed in 69 of these 79 patients. This revealed a mean angiographic stenosis of 30±17% (2-72%). Greater than 50% stenosis was found in 13 (13/69; 33%) patients. Importantly however, there was no incidence of new claudication on follow-up (median 17 months).

Conclusions: Our data suggest that in selected patients determined by an MDT, pTAVI under local anaesthesia is feasible, safe and probably desirable, particularly in the older patients. Surprisingly, lower logistic EuroSCORE and not BMI was a significant factor favouring the use of local anaesthesia. The percutaneous transfemoral approach and subsequent pre-closure using the Prostar device appear to have satisfactory acute and long-term vascular outcomes even in patients who had a significant degree of angiographic stenosis after device closure.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJY15M03_05 Jun 20, 2016
Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry
Petronio AS et al
free

CLINICAL RESEARCH

10.4244/EIJV11I6A137 Oct 20, 2015
Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation
Barbanti M et al
free

10.4244/EIJV9SSA7 Sep 15, 2013
Subclavian TAVI: more than an alternative access route
Petronio AS et al
free
Trending articles
334.8

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
33.05

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved